Literature DB >> 27647306

The Future for Dementia Research: a Perspective from the Journal of Molecular Neuroscience.

Illana Gozes1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27647306     DOI： 10.1007/s12031-016-0841-5

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN： 0895-8696            Impact factor:   3.444


× No keyword cloud information.
  21 in total

1.  Tau as a drug target in Alzheimer's disease.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

2.  Tau and Alzheimer's disease: the long road to anti-tangle therapeutics.

Authors:  Howard M Fillit; Lorenzo M Refolo
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

3.  Strategies for drug discovery for cognitive aging and Alzheimer's disease.

Authors:  Howard M Fillit; Alan W O'Connell; Lorenzo M Refolo
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

4.  Introduction to the Special Issue on Spinal and Bulbar Muscular Atrophy.

Authors:  Maria Pennuto; Illana Gozes
Journal:  J Mol Neurosci       Date:  2016-02-13       Impact factor: 3.444

Review 5.  Addressing Alzheimer's disease tangles: from NAP to AL-108.

Authors:  Illana Gozes; Alistair Stewart; Bruce Morimoto; Anthony Fox; Karole Sutherland; Donald Schmeche
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

6.  Dementia Research Australia: the Australian Dementia Research Development Fellowship Program.

Authors:  Ashley I Bush; George Fink; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-11       Impact factor: 3.444

Review 7.  Metallostasis in Alzheimer's disease.

Authors:  Scott Ayton; Peng Lei; Ashley I Bush
Journal:  Free Radic Biol Med       Date:  2012-11-09       Impact factor: 7.376

8.  Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ Study.

Authors:  Claudia H Kawas; Dana E Greenia; Szofia S Bullain; Christopher M Clark; Michael J Pontecorvo; Abhinay D Joshi; María M Corrada
Journal:  Alzheimers Dement       Date:  2012-11-16       Impact factor: 21.566

9.  Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

Authors:  Stephen Salloway; Reisa Sperling; H Robert Brashear
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

10.  Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Authors:  C L Masters; G Simms; N A Weinman; G Multhaup; B L McDonald; K Beyreuther
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.